Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-JM
NCT07794774Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
A Phase 3 trial of berobenatide in obesity, sponsored by Pfizer. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
berobenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07794774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794774.